Key highlights

  • Echo IQ said on 12 October 2026 that it filed a request for supervisory review of the FDA’s Not Substantially Equivalent determination, and that the appeal was accepted.
  • A meeting with the FDA is expected within 30 days of that announcement.
  • On 17 September 2026 the company said the FDA’s cited matters related to statistical analysis supporting clinical validation, and that its strategic partner agreements were not materially affected.

On 21 October 2026, Echoiq Ltd (ASX:EIQ) shares were higher by 0.61% at $0.413 during the trading session. Benchmarks for the session included the S&P/ASX 200 Info Tech [XIJ] at 1,614.00, lower by 3.38% or 56.50 points, and the S&P/ASX 200 [XJO] at 8,811.10, lower by 0.066% or 5.80 points, at 3:12 pm GMT+11. On Wall Street on Tuesday, the Dow Jones Industrial Average climbed 1.02% to 52,495.88 and the S&P 500 gained 0.28% to 7,712.57, while the Nasdaq Composite fell about 0.02% to 26,424.82, with several large technology shares retreating as investors weighed valuations and upcoming results. Echo IQ is a Sydney-based AI and medical technology company that develops software for clinical decision-making in cardiology.

What Echo IQ does

Echo IQ Limited develops AI software to improve clinical decision-making in cardiology. Its flagship product, EchoSolv AS, is FDA-cleared as a clinical decision support aid in the detection of severe aortic stenosis. The company is headquartered in Sydney, with US operations based in Greenville, Delaware, and it is developing EchoSolv HF for heart failure.

FDA determination and initial update

In an announcement dated 17 September 2026, Echo IQ updated the market on its EchoSolv HF 510(k) application after receiving a Not Substantially Equivalent (NSE) determination from the US Food and Drug Administration, referred to in an announcement of 8 September 2026. The company said the matters cited relate to aspects of the statistical analysis supporting clinical validation and that its review had not identified concerns about the underlying technology or core functionality of the device.

It identified several pathways: an administrative appeal, review through the FDA Ombudsman or a new 510(k) submission. It said an appeal could lead to the NSE determination being overturned, the FDA reopening its review or the FDA asking the company to resubmit with clarity on matters to address, and that timelines are not strictly defined but may be shorter than 90 days in certain circumstances.

Administrative appeal filed

In an announcement dated 12 October 2026, Echo IQ advised that it has filed a request for supervisory review, an administrative appeal, of the FDA’s NSE determination for EchoSolv HF. It said the appeal has been accepted by the regulator and the FDA’s ombudsman has been informed. A meeting with the FDA connected with the appeal is expected within the next 30 days, after which the company anticipates greater clarity on the regulatory path for EchoSolv HF.

Partner agreements

In the 17 September 2026 release, Echo IQ stated that there has been no material impact to its strategic partner agreements, including those with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. Its forward-looking statements also refer to a convertible note arrangement with Pro Medicus, including a further A$10 million Investment Tranche that is conditional on FDA clearance of EchoSolv HF.

Sector context

Technology shares are being assessed against Earnings and valuations. During the session, the S&P/ASX 200 Info Tech index was at 1,614.00, down 3.38%, and the broader S&P/ASX 200 was at 8,811.10. In the United States, the Nasdaq is described as sensitive to corporate earnings and forward guidance and to artificial intelligence infrastructure spending. Medical AI software depends on regulatory clearance, and the company’s statements refer to US reimbursement proposals from CMS and to a proposed Software as a Medical Service payment methodology.

Risks and uncertainties

The FDA found the application Not Substantially Equivalent, and the company’s own statements note risks that a revised or new submission may not be made or may not succeed, and that clearance may not be obtained within any timeframe or at all. Commercial plans for EchoSolv HF remain subject to clearance, and the Pro Medicus tranche is conditional on it. The company’s statements also refer to risks around the CMS proposed rule being finalised, reimbursement policy, US commercial expansion and competition.

Catalysts to watch

Items to watch include the FDA meeting expected within 30 days of 12 October 2026, the outcome of the administrative appeal, a possible resubmission or new 510(k), and further updates on the partner arrangements.

Closing perspective

Echo IQ’s 17 September and 12 October 2026 announcements describe an appeal process following the FDA’s NSE decision, with an FDA meeting expected in the weeks after the second release. Updates would be provided as developments occur.